Tivic Health Systems, Inc. (NASDAQ:TIVC) Sees Large Decline in Short Interest

Posted by Donna Armstrong on Nov 16th, 2024

Tivic Health Systems, Inc. (NASDAQ:TIVC – Get Free Report) was the target of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 111,300 shares, a decrease of 32.7% from the October 15th total of 165,300 shares. Based on an average daily trading volume, of 5,120,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 1.8% of the shares of the stock are short sold.

Tivic Health Systems Trading Down 21.1 %

Shares of Tivic Health Systems stock traded down $0.08 on Friday, hitting $0.29. 2,159,292 shares of the company were exchanged, compared to its average volume of 3,192,011. Tivic Health Systems has a 1-year low of $0.22 and a 1-year high of $3.21. The company has a 50-day moving average price of $0.28 and a 200 day moving average price of $0.39.

Tivic Health Systems (NASDAQ:TIVC – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.32) EPS for the quarter. The business had revenue of $0.14 million during the quarter. Tivic Health Systems had a negative return on equity of 172.08% and a negative net margin of 606.47%.

Institutional Trading of Tivic Health Systems

An institutional investor recently bought a new position in Tivic Health Systems stock. Warberg Asset Management LLC bought a new position in Tivic Health Systems, Inc. (NASDAQ:TIVC – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 80,000 shares of the company’s stock, valued at approximately $31,000. Warberg Asset Management LLC owned about 1.29% of Tivic Health Systems as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 4.25% of the company’s stock.

Tivic Health Systems Company Profile

(Get Free Report)

Tivic Health Systems Inc operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S.